DLH Appoints Chief Scientist
November 05 2020 - 11:00AM
DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the
“Company”), a leading provider of innovative
healthcare research, services and solutions to the federal
government, today announced Sandra Halverson, MPH, PhD has been
appointed Chief Scientist effective November 1, 2020. In this role,
Dr. Halverson will work collaboratively with the DLH Executive
Leadership Team to help set company research and scientific
priorities. In addition to research coordination and personnel
management duties, Sandra will serve as a public representative of
the company, helping tell the story of DLH’s increasingly prominent
role in the public health and life sciences market space.
Dr. Halverson currently serves as Director of DLH’s Survey
Operations Center and as Project Director for the DLH-supported
NIEHS Sister Study, a landmark research effort dedicated to finding
the causes of breast cancer.
“We are thrilled that Sandra is taking on this larger role
within DLH,” said Jeanine Christian, President of DLH’s Public
Health and Scientific Research operating unit. “Her combination of
discipline-specific knowledge, leadership skills, and business
know-how will strengthen the competitive position of our company
and ensure DLH is at the forefront of the latest scientific and
technological advances.”
Dr. Halverson joined DLH in 2012 from her tenure-tracked
position as Assistant Professor of Medicine at Vanderbilt
University; she served as the Associate Director of Graduate
Studies for the school’s Institute for Medicine and Public Health
doctoral program in epidemiology. Sandra holds a PhD in
Epidemiology from the University of North Carolina, Chapel Hill, as
well as a Master of Public Health in Epidemiology and Biostatistics
from The George Washington University School of Public Health and
Health Services.
“This appointment will help build upon DLH’s position in the
Public Health & Life Sciences market area,” said DLH President
and CEO, Zach Parker. "In this time of public health crisis, our
solutions in epidemiology, clinical trials, biomedical &
environmental research including longitudinal studies, health
policy analytics, and program evaluation are more vital than
ever.”
About DLHDLH (NASDAQ: DLHC) serves federal
government clients throughout the United States and abroad
delivering technology enabled solutions in key health and human
services programs. The Company's core competencies include secure
data analytics, clinical trials and laboratory services, case
management, performance evaluation, system modernization,
operational logistics and readiness, and strategic digital
communications. DLH has approximately 2,000 employees serving
numerous government agencies. For more information, visit the
corporate website at www.dlhcorp.com
CONTACTS:INVESTOR RELATIONSContact: Chris
WittyPhone:
646-438-9385Email: cwitty@darrowir.com
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Apr 2023 to Apr 2024